Last Updated : May 6, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Libtayo | Cemiplimab | Advanced Cutaneous Squamous Cell Carcinoma (CSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ilumya | tildrakizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Darzalex | Daratumumab | Rd for MM | Reimburse with clinical criteria and/or conditions | Complete | ||
| Crysvita | burosumab | Treatment of X-Linked Hypophosphatemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Baqsimi | glucagon | Severe hypoglycemic reactions | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
| TBD | Entrectinib | Withdrawn | ||||
| Keytruda | Pembrolizumab | Renal Cell Carcinoma (RCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Mylotarg | Gemtuzumab Ozogamicin | Acute Myeloid Leukemia (AML) | Reimburse | Complete | ||
| Stelara/Stelara I.V | ustekinumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 6, 2024